Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions

Progress in Retinal and Eye Research

Volumn 34, Issue , 2013, Pages 19-48

  Klaassen, Ingeborg ^a   Van Noorden, Cornelis J F ^b   Schlingemann, Reinier O ^a,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

Blood retinal barrier; Capillary permeability; Caveolae; Diabetic macular edema; Diabetic retinopathy; Endothelium; Pericytes; Retina; Tight junctions; Transcytosis; Vascular endothelial growth factor A antagonists inhibitors

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BETA CATENIN; BETAMETHASONE; BEVASIRANIB; BROMFENAC; CHOLINE FENOFIBRATE; CLAUDIN 1; CLAUDIN 2; CLAUDIN 5; CORTICOSTEROID; CYTOKINE; DARAPLADIB; DEXTROMETHORPHAN; DICLOFENAC; GAP JUNCTION PROTEIN; GROWTH FACTOR; INFLIXIMAB; LIFITEGRAST; MECAMYLAMINE; MINOCYCLINE; NERVE CELL ADHESION MOLECULE; NONSTEROID ANTIINFLAMMATORY AGENT; OCCLUDIN; PEGAPTANIB; PLASMA PROTEIN; RAPAMYCIN; SAFOTIBANT; THIOCTIC ACID; UNINDEXED DRUG; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL CELL; BASEMENT MEMBRANE; BLOOD RETINA BARRIER; BLOOD VESSEL WALL; CELL JUNCTION; CELL MEMBRANE PERMEABILITY; DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG TRANSPORT; ENDOTHELIUM CELL; GLYCOCALYX; HYPERGLYCEMIA; INFLAMMATION; NONHUMAN; OSMOTIC PRESSURE; OXIDATIVE STRESS; PERICYTE; PRIORITY JOURNAL; QUALITY OF LIFE; RETROLENTAL FIBROPLASIA; REVIEW; TRANSCYTOSIS;

BLOOD-RETINAL BARRIER; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; HUMANS; MACULAR EDEMA;

EID: 84876729820     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2013.02.001     Document Type: Review

References (434)

1. Abbott N.J. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell. Mol. Neurobiol. 2000, 20:131-147.
2. Abu el Asrar A.M., Maimone D., Morse P.H., Gregory S., Reder A.T. Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 1992, 114:731-736.
3. Adamis A.P., Berman A.J. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin. Immunopathol. 2008, 30:65-84.
4. Aiello L.P., Pierce E.A., Foley E.D., Takagi H., Chen H., Riddle L., Ferrara N., King G.L., Smith L.E. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:10457-10461.
5. Aiello L.P., Bursell S.E., Clermont A., Duh E., Ishii H., Takagi C., Mori F., Ciulla T.A., Ways K., Jirousek M., Smith L.E., King G.L. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997, 46:1473-1480.
6. Aiello L.P. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv. Ophthalmol. 2002, 47(Suppl 2):S263-S269.
7. Al-Ahmad A., Gassmann M., Ogunshola O.O. Maintaining blood-brain barrier integrity: pericytes perform better than astrocytes during prolonged oxygen deprivation. J. Cell. Physiol. 2009, 218:612-622.
8. Alam M.I., Beg S., Samad A., Baboota S., Kohli K., Ali J., Ahuja A., Akbar M. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci. 2010, 40:385-403.
9. Al-Latayfeh M., Silva P.S., Sun J.K., Aiello L.P. Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb. Perspect. Med. 2012, 2:a006411.
10. Anderson R.G. Caveolae: where incoming and outgoing messengers meet. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:10909-10913.
11. Anderson R.G. Transendothelial movement and caveolae. Nat. Biotechnol. 2008, 26:380-381.
12. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008, 22:1276-1312.
13. Anthony D.C., Bolton S.J., Fearn S., Perry V.H. Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brain barrier permeability in rats. Brain 1997, 120:435-444.
14. Antonelli-Orlidge A., Smith S.R., D'Amore P.A. Influence of pericytes on capillary endothelial cell growth. Am. Rev. Respir. Dis. 1989, 140:1129-1131.
15. Antonetti D.A., Barber A.J., Khin S., Lieth E., Tarbell J.M., Gardner T.W. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 1998, 47:1953-1959. Penn State Retina Research Group.
16. Antonetti D.A., Barber A.J., Hollinger L.A., Wolpert E.B., Gardner T.W. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J. Biol. Chem. 1999, 274:23463-23467.
17. Antonetti D.A., Wolpert E.B., DeMaio L., Harhaj N.S., Scaduto R.C. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J. Neurochem. 2002, 80:667-677.
18. Arden G.B., Sidman R.L., Arap W., Schlingemann R.O. Spare the rod and spoil the eye. Br. J. Ophthalmol. 2005, 89:764-769.
19. Armstrong S.M., Khajoee V., Wang C., Wang T., Tigdi J., Yin J., Kuebler W.M., Gillrie M., Davis S.P., Ho M., Lee W.L. Co-regulation of transcellular and paracellular leak across microvascular endothelium by dynamin and Rac. Am. J. Pathol. 2012, 180:1308-1323.
20. Armulik A., Genove G., Mae M., Nisancioglu M.H., Wallgard E., Niaudet C., He L., Norlin J., Lindblom P., Strittmatter K., Johansson B.R., Betsholtz C. Pericytes regulate the blood-brain barrier. Nature 2010, 468:557-561.
21. Armulik A., Genove G., Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell. 2011, 21:193-215.
22. Aroca P.R., Salvat M., Fernandez J., Mendez I. Risk factors for diffuse and focal macular edema. J. Diabetes Complications 2004, 18:211-215.
23. Asahara T., Chen D., Takahashi T., Fujikawa K., Kearney M., Magner M., Yancopoulos G.D., Isner J.M. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ. Res. 1998, 83:233-240.
24. Ayalon O., Sabanai H., Lampugnani M.G., Dejana E., Geiger B. Spatial and temporal relationships between cadherins and PECAM-1 in cell-cell junctions of human endothelial cells. J. Cell Biol. 1994, 126:247-258.
25. Balda M.S., Whitney J.A., Flores C., Gonzalez S., Cereijido M., Matter K. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J. Cell Biol. 1996, 134:1031-1049.
26. Bamforth S.D., Lightman S.L., Greenwood J. Ultrastructural analysis of interleukin-1 beta-induced leukocyte recruitment to the rat retina. Invest. Ophthalmol. Vis. Sci. 1997, 38:25-35.
27. Barber A.J., Antonetti D.A., Gardner T.W. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. Invest. Ophthalmol. Vis. Sci. 2000, 41:3561-3568. The Penn State Retina Research Group.
28. Barber A.J., Antonetti D.A. Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats. Invest. Ophthalmol. Vis. Sci. 2003, 44:5410-5416.
29. Bauer H.-C., Traweger A., Bauer H. Proteins of the tight junction in the blood-brain barrier. Blood-Spinal Cord and Brain Barriers in Health and Disease 2004, 1-10. Elsevier, San Diego. H.S. Sharma, J. Westman (Eds.).
30. Bazzoni G., Dejana E., Lampugnani M.G. Endothelial adhesion molecules in the development of the vascular tree: the garden of forking paths. Curr. Opin. Cell Biol. 1999, 11:573-581.
31. Bazzoni G., Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol. Rev. 2004, 84:869-901.
32. Beck R.W., Edwards A.R., Aiello L.P., Bressler N.M., Ferris F., Glassman A.R., Hartnett E., Ip M.S., Kim J.E., Kollman C. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch. Ophthalmol. 2009, 127:245-251.
33. Behzadian M.A., Wang X.L., Windsor L.J., Ghaly N., Caldwell R.B. TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function. Invest. Ophthalmol. Vis. Sci. 2001, 42:853-859.
34. Bell R.D., Winkler E.A., Sagare A.P., Singh I., LaRue B., Deane R., Zlokovic B.V. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010, 68:409-427.
35. Beltramo E., Pomero F., Allione A., D'Alu F., Ponte E., Porta M. Pericyte adhesion is impaired on extracellular matrix produced by endothelial cells in high hexose concentrations. Diabetologia 2002, 45:416-419.
36. Bienz M., Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000, 103:311-320.
37. Boado R.J., Pardridge W.M. The Trojan Horse liposome technology for nonviral gene transfer across the blood-brain barrier. J. Drug Deliv. 2011, 2011:296151.
38. Bobbie M.W., Roy S., Trudeau K., Munger S.J., Simon A.M., Roy S. Reduced connexin 43 expression and its effect on the development of vascular lesions in retinas of diabetic mice. Invest. Ophthalmol. Vis. Sci. 2010, 51:3758-3763.
39. Bochaton-Piallat M.L., Kapetanios A.D., Donati G., Redard M., Gabbiani G., Pournaras C.J. TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2000, 41:2336-2342.
40. Bolton S.J., Anthony D.C., Perry V.H. Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience 1998, 86:1245-1257.
41. Bolton W.K., Cattran D.C., Williams M.E., Adler S.G., Appel G.B., Cartwright K., Foiles P.G., Freedman B.I., Raskin P., Ratner R.E., Spinowitz B.S., Whittier F.C., Wuerth J.P. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 2004, 24:32-40.
42. Bosco A., Cusato K., Nicchia G.P., Frigeri A., Spray D.C. A developmental switch in the expression of aquaporin-4 and Kir4.1 from horizontal to Muller cells in mouse retina. Invest. Ophthalmol. Vis. Sci. 2005, 46:3869-3875.
43. Bradbury M.W. The blood-brain barrier. Transport across the cerebral endothelium. Circ. Res. 1985, 57:213-222.
44. Braga V.M. Cell-cell adhesion and signalling. Curr. Opin. Cell Biol. 2002, 14:546-556.
45. Brankin B., Campbell M., Canning P., Gardiner T.A., Stitt A.W. Endostatin modulates VEGF-mediated barrier dysfunction in the retinal microvascular endothelium. Exp. Eye Res. 2005, 81:22-31.
46. Bringmann A., Pannicke T., Grosche J., Francke M., Wiedemann P., Skatchkov S.N., Osborne N.N., Reichenbach A. Muller cells in the healthy and diseased retina. Prog. Retin. Eye Res. 2006, 25:397-424.
47. Broekhuizen L.N., Lemkes B.A., Mooij H.L., Meuwese M.C., Verberne H., Holleman F., Schlingemann R.O., Nieuwdorp M., Stroes E.S., Vink H. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010, 53:2646-2655.
48. Brooks H.L., Caballero S., Newell C.K., Steinmetz R.L., Watson D., Segal M.S., Harrison J.K., Scott E.W., Grant M.B. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch. Ophthalmol. 2004, 122:1801-1807.
49. Brosnan C.F., Litwak M.S., Schroeder C.E., Selmaj K., Raine C.S., Arezzo J.C. Preliminary studies of cytokine-induced functional effects on the visual pathways in the rabbit. J. Neuroimmunol. 1989, 25:227-239.
50. Browning D.J., Altaweel M.M., Bressler N.M., Bressler S.B., Scott I.U. Diabetic macular edema: what is focal and what is diffuse?. Am. J. Ophthalmol. 2008, 146:649-655.
51. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
52. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
53. Bruns A.F., Bao L., Walker J.H., Ponnambalam S. VEGF-A-stimulated signalling in endothelial cells via a dual receptor tyrosine kinase system is dependent on co-ordinated trafficking and proteolysis. Biochem. Soc. Trans. 2009, 37:1193-1197.
54. Bruns R.R., Palade G.E. Studies on blood capillaries. II. Transport of ferritin molecules across the wall of muscle capillaries. J. Cell Biol. 1968, 37:277-299.
55. Bundgaard M., Frokjaer-Jensen J., Crone C. Endothelial plasmalemmal vesicles as elements in a system of branching invaginations from the cell surface. Proc. Natl. Acad. Sci. U.S.A. 1979, 76:6439-6442.
56. Butt A.M., Jones H.C., Abbott N.J. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J. Physiol. 1990, 429:47-62.
57. Cai J., Wu L., Qi X., Li C.S., Caballero S., Shaw L., Ruan Q., Grant M.B., Boulton M.E. PEDF regulates vascular permeability by a gamma-secretase-mediated pathway. PLoS One 2011, 6:e21164.
58. Cai J., Wu L., Qi X., Shaw L., Li C.S., Caballero S., Jiang W.G., Vinores S.A., Antonetti D., Ahmed A., Grant M.B., Boulton M.E. Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability. PLoS One 2011, 6:e18076.
59. Callanan D., Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin. Ophthalmol. 2008, 2:689-692.
60. Campbell M., Kiang A.S., Kenna P.F., Kerskens C., Blau C., O'Dwyer L., Tivnan A., Kelly J.A., Brankin B., Farrar G.J., Humphries P. RNAi-mediated reversible opening of the blood-brain barrier. J. Gene Med. 2008, 10:930-947.
61. Campbell M., Ozaki E., Humphries P. Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach. Expert Opin. Drug Deliv. 2010, 7:859-869.
62. Carman C.V., Springer T.A. Trans-cellular migration: cell-cell contacts get intimate. Curr. Opin. Cell Biol. 2008, 20:533-540.
63. Carson-Walter E.B., Hampton J., Shue E., Geynisman D.M., Pillai P.K., Sathanoori R., Madden S.L., Hamilton R.L., Walter K.A. Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumor angiogenesis. Clin. Cancer Res. 2005, 11:7643-7650.
64. Cavallaro U., Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 2004, 4:118-132.
65. Cavey M., Rauzi M., Lenne P.F., Lecuit T. A two-tiered mechanism for stabilization and immobilization of E-cadherin. Nature 2008, 453:751-756.
66. Cecchelli R., Berezowski V., Lundquist S., Culot M., Renftel M., Dehouck M.P., Fenart L. Modelling of the blood-brain barrier in drug discovery and development. Nat. Rev. Drug Discov. 2007, 6:650-661.
67. Chen Y., Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 2011, 64:640-665.
68. Chen Y.H., Lin S.J., Lin F.Y., Wu T.C., Tsao C.R., Huang P.H., Liu P.L., Chen Y.L., Chen J.W. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 2007, 56:1559-1568.
69. Cheung N., Tikellis G., Wang J.J. Diabetic retinopathy. Ophthalmology 2007, 114:2098-2099.
70. Chiba H., Osanai M., Murata M., Kojima T., Sawada N. Transmembrane proteins of tight junctions. Biochim. Biophys. Acta 2008, 1778:588-600.
71. Choi Y.K., Kim J.H., Kim W.J., Lee H.Y., Park J.A., Lee S.W., Yoon D.K., Kim H.H., Chung H., Yu Y.S., Kim K.W. AKAP12 regulates human blood-retinal barrier formation by downregulation of hypoxia-inducible factor-1alpha. J. Neurosci. 2007, 27:4472-4481.
72. Chronopoulos A., Trudeau K., Roy S., Huang H., Vinores S.A., Roy S. High glucose-induced altered basement membrane composition and structure increases trans-endothelial permeability: implications for diabetic retinopathy. Curr. Eye Res. 2011, 36:747-753.
73. Churdchomjan W., Kheolamai P., Manochantr S., Tapanadechopone P., Tantrawatpan C., Pratya Y., Issaragrisil S. Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control. BMC Endocr. Disord. 2010, 10:5.
74. Claudio L., Martiney J.A., Brosnan C.F. Ultrastructural studies of the blood-retina barrier after exposure to interleukin-1 beta or tumor necrosis factor-alpha. Lab. Invest. 1994, 70:850-861.
75. Collins J., Fleming T. Specific mRNA detection in single lineage-marked blastomeres from preimplantation embryos. Trends Genet. 1995, 11:5-7.
76. Connor T.B., Roberts A.B., Sporn M.B., Danielpour D., Dart L.L., Michels R.G., de B.S., Enger C., Kato H., Lansing M. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J. Clin. Invest. 1989, 83:1661-1666.
77. Cui B., Sun J.H., Xiang F.F., Liu L., Li W.J. Aquaporin 4 knockdown exacerbates streptozotocin-induced diabetic retinopathy through aggravating inflammatory response. Exp. Eye Res. 2012, 98:37-43.
78. Cui J.Z., Chiu A., Maberley D., Ma P., Samad A., Matsubara J.A. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye (Lond) 2007, 21:200-208.
79. Cunha-Vaz J.G. Studies on the pathophysiology of diabetic retinopathy. The blood-retinal barrier in diabetes. Diabetes 1983, 32(Suppl 2):20-27.
80. Cunha-Vaz J.G., Travassos A. Breakdown of the blood-retinal barriers and cystoid macular edema. Surv. Ophthalmol. 1984, 28:485-492.
81. Cunha-Vaz J.G. The blood-ocular barriers: past, present, and future. Doc. Ophthalmol. 1997, 93:149-157.
82. Cunha-Vaz J. Diabetic macular edema. Eur. J. Ophthalmol. 1998, 8:127-130.
83. D'Amore P.A. Mechanisms of retinal and choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 1994, 35:3974-3979.
84. Da T., Verkman A.S. Aquaporin-4 gene disruption in mice protects against impaired retinal function and cell death after ischemia. Invest. Ophthalmol. Vis. Sci. 2004, 45:4477-4483.
85. Daneman R., Zhou L., Kebede A.A., Barres B.A. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010, 468:562-566.
86. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., Ryan T.E., Bruno J., Radziejewski C., Maisonpierre P.C., Yancopoulos G.D. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87:1161-1169.
87. De Bock M., Culot M., Wang N., Bol M., Decrock E., De V.E., da C.A., Dauwe I., Vinken M., Simon A.M., Rogiers V., De L.G., Evans W.H., Bultynck G., Dupont G., Cecchelli R., Leybaert L. Connexin channels provide a target to manipulate brain endothelial calcium dynamics and blood-brain barrier permeability. J. Cereb. Blood Flow Metab. 2011, 31:1942-1957.
88. Dejana E. Endothelial cell-cell junctions: happy together. Nat. Rev. Mol. Cell Biol. 2004, 5:261-270.
89. Dejana E., Orsenigo F., Lampugnani M.G. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J. Cell Sci. 2008, 121:2115-2122.
90. Dejana E., Giampietro C. Vascular endothelial-cadherin and vascular stability. Curr. Opin. Hematol. 2012, 19:218-223.
91. Deli M.A., Abraham C.S., Kataoka Y., Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell. Mol. Neurobiol. 2005, 25:59-127.
92. DeMaio L., Chang Y.S., Gardner T.W., Tarbell J.M., Antonetti D.A. Shear stress regulates occludin content and phosphorylation. Am. J. Physiol. Heart Circ. Physiol. 2001, 281:H105-H113.
93. DeMaio L., Rouhanizadeh M., Reddy S., Sevanian A., Hwang J., Hsiai T.K. Oxidized phospholipids mediate occludin expression and phosphorylation in vascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H674-H683.
94. Demerath E.W., Cameron N., Gillman M.W., Towne B., Siervogel R.M. Telomeres and telomerase in the fetal origins of cardiovascular disease: a review. Hum. Biol. 2004, 76:127-146.
95. Demircan N., Safran B.G., Soylu M., Ozcan A.A., Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) 2006, 20:1366-1369.
96. Dewever J., Frerart F., Bouzin C., Baudelet C., Ansiaux R., Sonveaux P., Gallez B., Dessy C., Feron O. Caveolin-1 is critical for the maturation of tumor blood vessels through the regulation of both endothelial tube formation and mural cell recruitment. Am. J. Pathol. 2007, 171:1619-1628.
97. Diaz-Flores L., Gutierrez R., Madrid J.F., Varela H., Valladares F., Acosta E., Martin-Vasallo P., Diaz-Flores L. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol. Histopathol. 2009, 24:909-969.
98. Distler C., Dreher Z. Glia cells of the monkey retina-II. Muller cells. Vis. Res. 1996, 36:2381-2394.
99. Ditzel J. Oxygen transport impairment in diabetes. Diabetes 1976, 25:832-838.
100. Dohgu S., Takata F., Yamauchi A., Nakagawa S., Egawa T., Naito M., Tsuruo T., Sawada Y., Niwa M., Kataoka Y. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-beta production. Brain Res. 2005, 1038:208-215.
101. Dorfel M.J., Huber O. Modulation of tight junction structure and function by kinases and phosphatases targeting occludin. J. Biomed. Biotechnol. 2012, 2012:807356.
102. Drab M., Verkade P., Elger M., Kasper M., Lohn M., Lauterbach B., Menne J., Lindschau C., Mende F., Luft F.C., Schedl A., Haller H., Kurzchalia T.V. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001, 293:2449-2452.
103. Dyer M.A., Cepko C.L. Control of Muller glial cell proliferation and activation following retinal injury. Nat. Neurosci. 2000, 3:873-880.
104. Ebnet K., Suzuki A., Ohno S., Vestweber D. Junctional adhesion molecules (JAMs): more molecules with dual functions?. J. Cell Sci. 2004, 117:19-29.
105. Edo M.D., Andres V. Aging, telomeres, and atherosclerosis. Cardiovasc. Res. 2005, 66:213-221.
106. Eichler W., Kuhrt H., Hoffmann S., Wiedemann P., Reichenbach A. VEGF release by retinal glia depends on both oxygen and glucose supply. Neuroreport 2000, 11:3533-3537.
107. El-Mollayess G.M., Noureddine B.N., Bashshur Z.F. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment. Semin. Ophthalmol. 2011, 26:69-76.
108. Elkin M., Ilan N., Ishai-Michaeli R., Friedmann Y., Papo O., Pecker I., Vlodavsky I. Heparanase as mediator of angiogenesis: mode of action. FASEB J. 2001, 15:1661-1663.
109. Elner S.G., Strieter R., Bian Z.M., Kunkel S., Mokhtarzaden L., Johnson M., Lukacs N., Elner V.M. Interferon-induced protein 10 and interleukin 8. C-X-C chemokines present in proliferative diabetic retinopathy. Arch. Ophthalmol. 1998, 116:1597-1601.
110. Endo M., Jain R.K., Witwer B., Brown D. Water channel (aquaporin 1) expression and distribution in mammary carcinomas and glioblastomas. Microvasc. Res. 1999, 58:89-98.
111. Enge M., Bjarnegard M., Gerhardt H., Gustafsson E., Kalen M., Asker N., Hammes H.P., Shani M., Fassler R., Betsholtz C. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J. 2002, 21:4307-4316.
112. Engelhardt B., Wolburg H. Mini-review: transendothelial migration of leukocytes: through the front door or around the side of the house?. Eur. J. Immunol. 2004, 34:2955-2963.
113. Esser S., Lampugnani M.G., Corada M., Dejana E., Risau W. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J. Cell Sci. 1998, 111:1853-1865.
114. Farquhar M.G., Palade G.E. Junctional complexes in various epithelia. J. Cell Biol. 1963, 17:375-412.
115. Felinski E.A., Cox A.E., Phillips B.E., Antonetti D.A. Glucocorticoids induce transactivation of tight junction genes occludin and claudin-5 in retinal endothelial cells via a novel cis-element. Exp. Eye Res. 2008, 86:867-878.
116. Feng Y., Venema V.J., Venema R.C., Tsai N., Behzadian M.A., Caldwell R.B. VEGF-induced permeability increase is mediated by caveolae. Invest. Ophthalmol. Vis. Sci. 1999, 40:157-167.
117. Feng Y., Venema V.J., Venema R.C., Tsai N., Caldwell R.B. VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells. Biochem. Biophys. Res. Commun. 1999, 256:192-197.
118. Ferrara N. Vascular endothelial growth factor. The trigger for neovascularization in the eye. Lab. Invest. 1995, 72:615-618.
119. Fisher M. Pericyte signaling in the neurovascular unit. Stroke 2009, 40:S13-S15.
120. Fletcher E.L., Downie L.E., Ly A., Ward M.M., Batcha A.H., Puthussery T., Yee P., Hatzopoulos K.M. A review of the role of glial cells in understanding retinal disease. Clin. Exp. Optom. 2008, 91:67-77.
121. Forster C., Burek M., Romero I.A., Weksler B., Couraud P.O., Drenckhahn D. Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J. Physiol. 2008, 586:1937-1949.
122. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16:4604-4613.
123. Frank P.G., Pavlides S., Lisanti M.P. Caveolae and transcytosis in endothelial cells: role in atherosclerosis. Cell. Tissue Res. 2009, 335:41-47.
124. Freddo T.F. A contemporary concept of the blood-aqueous barrier. Prog. Retin. Eye Res. 2013, 32:181-195.
125. Fukuda M., Nakanishi Y., Fuse M., Yokoi N., Hamada Y., Fukagawa M., Negi A., Nakamura M. Altered expression of aquaporins 1 and 4 coincides with neurodegenerative events in retinas of spontaneously diabetic Torii rats. Exp. Eye Res. 2010, 90:17-25.
126. Funatsu H., Yamashita H., Ikeda T., Mimura T., Eguchi S., Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003, 110:1690-1696.
127. Funatsu H., Yamashita H., Noma H., Mimura T., Nakamura S., Sakata K., Hori S. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch. Clin. Exp. Ophthalmol. 2005, 243:3-8.
128. Funk M., Schmidinger G., Maar N., Bolz M., Benesch T., Zlabinger G.J., Schmidt-Erfurth U.M. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina 2010, 30:1412-1419.
129. Furuse M., Hirase T., Itoh M., Nagafuchi A., Yonemura S., Tsukita S., Tsukita S. Occludin: a novel integral membrane protein localizing at tight junctions. J. Cell Biol. 1993, 123:1777-1788.
130. Furuse M., Sasaki H., Fujimoto K., Tsukita S. A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J. Cell Biol. 1998, 143:391-401.
131. Gaengel K., Genove G., Armulik A., Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:630-638.
132. Gaillard P.J., Voorwinden L.H., Nielsen J.L., Ivanov A., Atsumi R., Engman H., Ringbom C., de Boer A.G., Breimer D.D. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur. J. Pharm. Sci. 2001, 12:215-222.
133. Gao B.B., Clermont A., Rook S., Fonda S.J., Srinivasan V.J., Wojtkowski M., Fujimoto J.G., Avery R.L., Arrigg P.G., Bursell S.E., Aiello L.P., Feener E.P. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med. 2007, 13:181-188.
134. Garcia C.M., Darland D.C., Massingham L.J., D'Amore P.A. Endothelial cell-astrocyte interactions and TGF beta are required for induction of blood-neural barrier properties. Brain Res. Dev. Brain Res. 2004, 152:25-38.
135. Gardiner T.A., Stitt A.W., Archer D.B. Retinal vascular endothelial cell endocytosis increases in early diabetes. Lab. Invest. 1995, 72:439-444.
136. Gardiner T.A., Archer D.B., Curtis T.M., Stitt A.W. Arteriolar involvement in the microvascular lesions of diabetic retinopathy: implications for pathogenesis. Microcirculation 2007, 14:25-38.
137. Gardner T.W., Eller A.W., Friberg T.R., D'Antonio J.A., Hollis T.M. Antihistamines reduce blood-retinal barrier permeability in type I (insulin-dependent) diabetic patients with nonproliferative retinopathy. A pilot study. Retina 1995, 15:134-140.
138. Gardner T.W., Lieth E., Khin S.A., Barber A.J., Bonsall D.J., Lesher T., Rice K., Brennan W.A. Astrocytes increase barrier properties and ZO-1 expression in retinal vascular endothelial cells. Invest. Ophthalmol. Vis. Sci. 1997, 38:2423-2427.
139. Gardner T.W., Antonetti D.A., Barber A.J., LaNoue K.F., Levison S.W. Diabetic retinopathy: more than meets the eye. Surv. Ophthalmol. 2002, 47(Suppl 2):S253-S262.
140. Gardner T.W., Sander B., Larsen M.L., Kunselman A., Tenhave T., Lund-Andersen H., Reimers J., Hubbard L., Blankenship G.W., Quillen D.A., Brod R.D., Wilmarth M.H., Post-Hansen H., Parving H.H., Davis M.D. An extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) system for grading of diabetic macular edema in the Astemizole Retinopathy Trial. Curr. Eye Res. 2006, 31:535-547.
141. Gaucher D., Chiappore J.A., Paques M., Simonutti M., Boitard C., Sahel J.A., Massin P., Picaud S. Microglial changes occur without neural cell death in diabetic retinopathy. Vis. Res. 2007, 47:612-623.
142. Gavard J., Gutkind J.S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat. Cell Biol. 2006, 8:1223-1234.
143. Gavard J., Patel V., Gutkind J.S. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev. Cell 2008, 14:25-36.
144. Gerhardt H., Wolburg H., Redies C. N-cadherin mediates pericytic-endothelial interaction during brain angiogenesis in the chicken. Dev. Dyn. 2000, 218:472-479.
145. Gerhardt H., Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell. Tissue Res. 2003, 314:15-23.
146. Geroski D.H., Edelhauser H.F. Drug delivery for posterior segment eye disease. Invest. Ophthalmol. Vis. Sci. 2000, 41:961-964.
147. Giebel S.J., Menicucci G., McGuire P.G., Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab. Invest. 2005, 85:597-607.
148. Gil J., Magno M. Fusion of pinocytotic vesicles in liquid filled lungs: a mechanism of cellular damage. Exp. Lung Res. 1980, 1:43-56.
149. Gleadle J.M., Ratcliffe P.J. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood 1997, 89:503-509.
150. Glenn J.V., Stitt A.W. The role of advanced glycation end products in retinal ageing and disease. Biochim. Biophys. Acta 2009, 1790:1109-1116.
151. Glenney J.R., Soppet D. Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:10517-10521.
152. Gonzalez-Mariscal L., Tapia R., Chamorro D. Crosstalk of tight junction components with signaling pathways. Biochim. Biophys. Acta 2008, 1778:729-756.
153. Goodyear M.J., Junghans B.M., Giummarra L., Murphy M.J., Crewther D.P., Crewther S.G. A role for aquaporin-4 during induction of form deprivation myopia in chick. Mol. Vis. 2008, 14:298-307.
154. Goodyear M.J., Crewther S.G., Junghans B.M. A role for aquaporin-4 in fluid regulation in the inner retina. Vis. Neurosci. 2009, 26:159-165.
155. Gratton J.P., Bernatchez P., Sessa W.C. Caveolae and caveolins in the cardiovascular system. Circ. Res. 2004, 94:1408-1417.
156. Greenwood J., Howes R., Lightman S. The blood-retinal barrier in experimental autoimmune uveoretinitis. Leukocyte interactions and functional damage. Lab. Invest. 1994, 70:39-52.
157. +-dependent adhesion molecules. Trends Biochem. Sci. 1988, 13:75-76.
158. Gumbiner B., Lowenkopf T., Apatira D. Identification of a 160-kDa polypeptide that binds to the tight junction protein ZO-1. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:3460-3464.
159. Gumbiner B.M. Regulation of cadherin adhesive activity. J. Cell. Biol. 2000, 148:399-404.
160. Hallmann R., Mayer D.N., Berg E.L., Broermann R., Butcher E.C. Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev. Dyn. 1995, 202:325-332.
161. Hamann S., Zeuthen T., La C.M., Nagelhus E.A., Ottersen O.P., Agre P., Nielsen S. Aquaporins in complex tissues: distribution of aquaporins 1-5 in human and rat eye. Am. J. Physiol. 1998, 274:C1332-C1345.
162. Hammes H.P., Martin S., Federlin K., Geisen K., Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:11555-11558.
163. Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., Lin J., Bierhaus A., Nawroth P., Hannak D., Neumaier M., Bergfeld R., Giardino I., Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 2003, 9:294-299.
164. Hammes H.P., Feng Y., Pfister F., Brownlee M. Diabetic retinopathy: targeting vasoregression. Diabetes 2011, 60:9-16.
165. Harhaj N.S., Antonetti D.A. Regulation of tight junctions and loss of barrier function in pathophysiology. Int. J. Biochem. Cell Biol. 2004, 36:1206-1237.
166. Harhaj N.S., Felinski E.A., Wolpert E.B., Sundstrom J.M., Gardner T.W., Antonetti D.A. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest. Ophthalmol. Vis. Sci. 2006, 47:5106-5115.
167. Hasegawa H., Lian S.C., Finkbeiner W.E., Verkman A.S. Extrarenal tissue distribution of CHIP28 water channels by in situ hybridization and antibody staining. Am. J. Physiol. 1994, 266:C893-C903.
168. Haskins J., Gu L., Wittchen E.S., Hibbard J., Stevenson B.R. ZO-3, a novel member of the MAGUK protein family found at the tight junction, interacts with ZO-1 and occludin. J. Cell Biol. 1998, 141:199-208.
169. Hayashi Y., Nomura M., Yamagishi S., Harada S., Yamashita J., Yamamoto H. Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia 1997, 19:13-26.
170. Henry C.B., Duling B.R. Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am. J. Physiol. 1999, 277:H508-H514.
171. Hill M.M., Bastiani M., Luetterforst R., Kirkham M., Kirkham A., Nixon S.J., Walser P., Abankwa D., Oorschot V.M., Martin S., Hancock J.F., Parton R.G. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell 2008, 132:113-124.
172. Hinton D.R., He S., Jin M.L., Barron E., Ryan S.J. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye (Lond) 2002, 16:422-428.
173. Hirase T., Staddon J.M., Saitou M., Ando-Akatsuka Y., Itoh M., Furuse M., Fujimoto K., Tsukita S., Rubin L.L. Occludin as a possible determinant of tight junction permeability in endothelial cells. J. Cell Sci. 1997, 110:1603-1613.
174. Hirase T., Kawashima S., Wong E.Y., Ueyama T., Rikitake Y., Tsukita S., Yokoyama M., Staddon J.M. Regulation of tight junction permeability and occludin phosphorylation by Rhoa-p160ROCK-dependent and -independent mechanisms. J. Biol. Chem. 2001, 276:10423-10431.
175. Hnasko R., McFarland M., Ben-Jonathan N. Distribution and characterization of plasmalemma vesicle protein-1 in rat endocrine glands. J. Endocrinol. 2002, 175:649-661.
176. Hofman P., Blaauwgeers H.G., Tolentino M.J., Adamis A.P., Nunes Cardozo B.J., Vrensen G.F., Schlingemann R.O. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A. Curr. Eye Res. 2000, 21:637-645.
177. Hofman P., Blaauwgeers H.G., Vrensen G.F., Schlingemann R.O. Role of VEGF-A in endothelial phenotypic shift in human diabetic retinopathy and VEGF-A-induced retinopathy in monkeys. Ophthalmic Res. 2001, 33:156-162.
178. Hofman P., Hoyng P., vanderWerf F., Vrensen G.F., Schlingemann R.O. Lack of blood-brain barrier properties in microvessels of the prelaminar optic nerve head. Invest. Ophthalmol. Vis. Sci. 2001, 42:895-901.
179. Hogeboom van Buggenum I.M., van der Heijde G.L., Tangelder G.J., Reichert-Thoen J.W. Ocular oxygen measurement. Br. J. Ophthalmol. 1996, 80:567-573.
180. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
181. Hollis T.M., Sill H.W., Butler C., Campos M.J., Gardner T.W. Astemizole reduces blood-retinal barrier leakage in experimental diabetes. J. Diabetes Complications 1992, 6:230-235.
182. Hori S., Ohtsuki S., Hosoya K., Nakashima E., Terasaki T. A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. J. Neurochem. 2004, 89:503-513.
183. Hosoya K., Yamamoto A., Akanuma S., Tachikawa M. Lipophilicity and transporter influence on blood-retinal barrier permeability: a comparison with blood-brain barrier permeability. Pharm. Res. 2010, 27:2715-2724.
184. Hosoya K., Tomi M., Tachikawa M. Strategies for therapy of retinal diseases using systemic drug delivery: relevance of transporters at the blood-retinal barrier. Expert Opin. Drug Deliv. 2011, 8:1571-1587.
185. Hughes J.M., Brink A., Witmer A.N., Hanraads-de R.M., Klaassen I., Schlingemann R.O. Vascular leucocyte adhesion molecules unaltered in the human retina in diabetes. Br. J. Ophthalmol. 2004, 88:566-572.
186. Hughes J.M., Kuiper E.J., Klaassen I., Canning P., Stitt A.W., Van Bezu J., Schalkwijk C.G., Van Noorden C.J., Schlingemann R.O. Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia 2007, 50:1089-1098.
187. Hughes J.M., Groot A.J., van der Groep P., Sersansie R., Vooijs M., van Diest P.J., Van Noorden C.J., Schlingemann R.O., Klaassen I. Active HIF-1 in the normal human retina. J. Histochem. Cytochem. 2010, 58:247-254.
188. Iandiev I., Pannicke T., Reichenbach A., Wiedemann P., Bringmann A. Diabetes alters the localization of glial aquaporins in rat retina. Neurosci. Lett. 2007, 421:132-136.
189. Ikegami-Kawai M., Okuda R., Nemoto T., Inada N., Takahashi T. Enhanced activity of serum and urinary hyaluronidases in streptozotocin-induced diabetic Wistar and GK rats. Glycobiology 2004, 14:65-72.
190. Ishii H., Jirousek M.R., Koya D., Takagi C., Xia P., Clermont A., Bursell S.E., Kern T.S., Ballas L.M., Heath W.F., Stramm L.E., Feener E.P., King G.L. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272:728-731.
191. Iyer N.V., Kotch L.E., Agani F., Leung S.W., Laughner E., Wenger R.H., Gassmann M., Gearhart J.D., Lawler A.M., Yu A.Y., Semenza G.L. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998, 12:149-162.
192. Jesaitis L.A., Goodenough D.A. Molecular characterization and tissue distribution of ZO-2, a tight junction protein homologous to ZO-1 and the Drosophila discs-large tumor suppressor protein. J. Cell Biol. 1994, 124:949-961.
193. Jiang B.H., Rue E., Wang G.L., Roe R., Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 1996, 271:17771-17778.
194. Jinga V.V., Gafencu A., Antohe F., Constantinescu E., Heltianu C., Raicu M., Manolescu I., Hunziker W., Simionescu M. Establishment of a pure vascular endothelial cell line from human placenta. Placenta 2000, 21:325-336.
195. Joussen A.M., Murata T., Tsujikawa A., Kirchhof B., Bursell S.E., Adamis A.P. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am. J. Pathol. 2001, 158:147-152.
196. Joussen A.M., Poulaki V., Qin W., Kirchhof B., Mitsiades N., Wiegand S.J., Rudge J., Yancopoulos G.D., Adamis A.P. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am. J. Pathol. 2002, 160:501-509.
197. Joussen A.M., Poulaki V., Le M.L., Koizumi K., Esser C., Janicki H., Schraermeyer U., Kociok N., Fauser S., Kirchhof B., Kern T.S., Adamis A.P. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004, 18:1450-1452.
198. Joussen A.M., Smyth N., Niessen C. Pathophysiology of diabetic macular edema. Dev. Ophthalmol. 2007, 39:1-12.
199. Joussen A.M., Doehmen S., Le M.L., Koizumi K., Radetzky S., Krohne T.U., Poulaki V., Semkova I., Kociok N. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis. 2009, 15:1418-1428.
200. Kashiwamura Y., Sano Y., Abe M., Shimizu F., Haruki H., Maeda T., Kawai M., Kanda T. Hydrocortisone enhances the function of the blood-nerve barrier through the up-regulation of claudin-5. Neurochem. Res. 2011, 36:849-855.
201. Kaur C., Sivakumar V., Foulds W.S. Early response of neurons and glial cells to hypoxia in the retina. Invest. Ophthalmol. Vis. Sci. 2006, 47:1126-1141.
202. Kaur C., Foulds W.S., Ling E.A. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog. Retin. Eye Res. 2008, 27:622-647.
203. Kevil C.G., Okayama N., Trocha S.D., Kalogeris T.J., Coe L.L., Specian R.D., Davis C.P., Alexander J.S. Expression of zonula occludens and adherens junctional proteins in human venous and arterial endothelial cells: role of occludin in endothelial solute barriers. Microcirculation 1998, 5:197-210.
204. Kim J., Kim C.S., Lee Y.M., Jo K., Shin S.D., Kim J.S. Methylglyoxal induces hyperpermeability of the blood-retinal barrier via the loss of tight junction proteins and the activation of matrix metalloproteinases. Graefes Arch. Clin. Exp. Ophthalmol. 2012, 250:691-697.
205. Kim J.H., Kim J.H., Yu Y.S., Kim D.H., Kim K.W. Recruitment of pericytes and astrocytes is closely related to the formation of tight junction in developing retinal vessels. J. Neurosci. Res. 2009, 87:653-659.
206. Kim S.Y., Johnson M.A., McLeod D.S., Alexander T., Hansen B.C., Lutty G.A. Neutrophils are associated with capillary closure in spontaneously diabetic monkey retinas. Diabetes 2005, 54:1534-1542.
207. Kimoto K., Kubota T. Anti-vegf agents for ocular angiogenesis and vascular permeability. J. Ophthalmol. 2012, 2012:852183.
208. King G.L., Johnson S.M. Receptor-mediated transport of insulin across endothelial cells. Science 1985, 227:1583-1586.
209. King G.L., Shiba T., Oliver J., Inoguchi T., Bursell S.E. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu. Rev. Med. 1994, 45:179-188.
210. Kita T., Hata Y., Kano K., Miura M., Nakao S., Noda Y., Shimokawa H., Ishibashi T. Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor. Diabetes 2007, 56:231-238.
211. Klaassen I., Hughes J.M., Vogels I.M., Schalkwijk C.G., Van Noorden C.J., Schlingemann R.O. Altered expression of genes related to blood-retina barrier disruption in streptozotocin-induced diabetes. Exp. Eye Res. 2009, 89:4-15.
212. Koh G.Y., Kim I., Kwak H.J., Yun M.J., Leem J.C. Biomedical significance of endothelial cell specific growth factor, angiopoietin. Exp. Mol. Med. 2002, 34:1-11.
213. Kojima T., Sawada N., Chiba H., Kokai Y., Yamamoto M., Urban M., Lee G.H., Hertzberg E.L., Mochizuki Y., Spray D.C. Induction of tight junctions in human connexin 32 (hCx32)-transfected mouse hepatocytes: connexin 32 interacts with occludin. Biochem. Biophys. Res. Commun. 1999, 266:222-229.
214. Kojima T., Spray D.C., Kokai Y., Chiba H., Mochizuki Y., Sawada N. Cx32 formation and/or Cx32-mediated intercellular communication induces expression and function of tight junctions in hepatocytic cell line. Exp. Cell Res. 2002, 276:40-51.
215. Komarova Y., Malik A.B. Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annu. Rev. Physiol. 2010, 72:463-493.
216. Korn J., Christ B., Kurz H. Neuroectodermal origin of brain pericytes and vascular smooth muscle cells. J. Comp. Neurol. 2002, 442:78-88.
217. Kucheryavykh Y.V., Kucheryavykh L.Y., Nichols C.G., Maldonado H.M., Baksi K., Reichenbach A., Skatchkov S.N., Eaton M.J. Downregulation of Kir4.1 inward rectifying potassium channel subunits by RNAi impairs potassium transfer and glutamate uptake by cultured cortical astrocytes. Glia 2007, 55:274-281.
218. Kuiper E.J., Witmer A.N., Klaassen I., Oliver N., Goldschmeding R., Schlingemann R.O. Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina. Br. J. Ophthalmol. 2004, 88:1082-1087.
219. Kuiper E.J., de Smet M.D., van Meurs J.C., Tan H.S., Tanck M.W., Oliver N., van Nieuwenhoven F.A., Goldschmeding R., Schlingemann R.O. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch. Ophthalmol. 2006, 124:1457-1462.
220. Kuiper E.J., Hughes J.M., Van Geest R.J., Vogels I.M., Goldschmeding R., Van Noorden C.J., Schlingemann R.O., Klaassen I. Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina. Invest. Ophthalmol. Vis. Sci. 2007, 48:4267-4276.
221. Kuiper E.J., van Nieuwenhoven F.A., de Smet M.D., van Meurs J.C., Tanck M.W., Oliver N., Klaassen I., Van Noorden C.J., Goldschmeding R., Schlingemann R.O. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One 2008, 3:e2675.
222. Kuiper E.J., van Z.R., Roestenberg P., Lyons K.M., Goldschmeding R., Klaassen I., Van Noorden C.J., Schlingemann R.O. Connective tissue growth factor is necessary for retinal capillary basal lamina thickening in diabetic mice. J. Histochem. Cytochem. 2008, 56:785-792.
223. Kurzchalia T.V., Dupree P., Parton R.G., Kellner R., Virta H., Lehnert M., Simons K. VIP21, a 21-kD membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. J. Cell Biol. 1992, 118:1003-1014.
224. Labrecque L., Royal I., Surprenant D.S., Patterson C., Gingras D., Beliveau R. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol. Biol. Cell 2003, 14:334-347.
225. Lal-Nag M., Morin P.J. The claudins. Genome Biol. 2009, 10:235.
226. Lampugnani M.G., Orsenigo F., Gagliani M.C., Tacchetti C., Dejana E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 2006, 174:593-604.
227. Lampugnani M.G. Endothelial Cell-to-cell Junctions: Adhesion and Signaling in Physiology and Pathology 2012, Cold Spring Harb, Perspect. Med. 2.
228. Lee S.W., Won J.Y., Lee H.Y., Lee H.J., Youn S.W., Lee J.Y., Cho C.H., Cho H.J., Oh S., Chae I.H., Kim H.S. Angiopoietin-1 protects heart against ischemia/reperfusion injury through VE-cadherin dephosphorylation and myocardiac integrin-beta1/ERK/caspase-9 phosphorylation cascade. Mol. Med. 2011, 17:1095-1106.
229. Lightman S., Greenwood J. Effect of lymphocytic infiltration on the blood-retinal barrier in experimental autoimmune uveoretinitis. Clin. Exp. Immunol. 1992, 88:473-477.
230. Limb G.A., Chignell A.H., Green W., LeRoy F., Dumonde D.C. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br. J. Ophthalmol. 1996, 80:168-173.
231. Lisanti M.P., Scherer P.E., Vidugiriene J., Tang Z., Hermanowski-Vosatka A., Tu Y.H., Cook R.F., Sargiacomo M. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J. Cell Biol. 1994, 126:111-126.
232. Liu L., Pilch P.F. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J. Biol. Chem. 2008, 283:4314-4322.
233. Lorenzi M. Glucose toxicity in the vascular complications of diabetes: the cellular perspective. Diabetes Metab. Rev. 1992, 8:85-103.
234. Lorenzi M., Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 2001, 44:791-804.
235. Lu Q., Harrington E.O., Jackson H., Morin N., Shannon C., Rounds S. Transforming growth factor-beta1-induced endothelial barrier dysfunction involves Smad2-dependent p38 activation and subsequent RhoA activation. J. Appl. Physiol. 2006, 101:375-384.
236. Luo Y., Xiao W., Zhu X., Mao Y., Liu X., Chen X., Huang J., Tang S., Rizzolo L.J. Differential expression of claudins in retinas during normal development and the angiogenesis of oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. 2011, 52:7556-7564.
237. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., Daly T.J., Davis S., Sato T.N., Yancopoulos G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
238. Mandriota S.J., Pepper M.S. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ. Res. 1998, 83:852-859.
239. Martiney J.A., Litwak M., Berman J.W., Arezzo J.C., Brosnan C.F. Pathophysiologic effect of interleukin-1b in the rabbit retina. Am. J. Pathol. 1990, 137:1411-1423.
240. Martiney J.A., Berman J.W., Brosnan C.F. Chronic inflammatory effects of interleukin-1 on the blood-retina barrier. J. Neuroimmunol. 1992, 41:167-176.
241. Matter K., Balda M.S. Holey barrier: claudins and the regulation of brain endothelial permeability. J. Cell Biol. 2003, 161:459-460.
242. McAllister I.L., Vijayasekaran S., Chen S.D., Yu D.Y. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am. J. Ophthalmol. 2009, 147:838-846.
243. Medina F.A., de Almeida C.J., Dew E., Li J., Bonuccelli G., Williams T.M., Cohen A.W., Pestell R.G., Frank P.G., Tanowitz H.B., Lisanti M.P. Caveolin-1-deficient mice show defects in innate immunity and inflammatory immune response during Salmonella enterica serovar Typhimurium infection. Infect. Immun. 2006, 74:6665-6674.
244. Mehta D., Malik A.B. Signaling mechanisms regulating endothelial permeability. Physiol. Rev. 2006, 86:279-367.
245. Michel C.C., Curry F.E. Microvascular permeability. Physiol. Rev. 1999, 79:703-761.
246. Milici A.J., Watrous N.E., Stukenbrok H., Palade G.E. Transcytosis of albumin in capillary endothelium. J. Cell Biol. 1987, 105:2603-2612.
247. Milovanova T., Chatterjee S., Hawkins B.J., Hong N., Sorokina E.M., Debolt K., Moore J.S., Madesh M., Fisher A.B. Caveolae are an essential component of the pathway for endothelial cell signaling associated with abrupt reduction of shear stress. Biochim. Biophys. Acta 2008, 1783:1866-1875.
248. Minshall R.D., Tiruppathi C., Vogel S.M., Niles W.D., Gilchrist A., Hamm H.E., Malik A.B. Endothelial cell-surface gp60 activates vesicle formation and trafficking via G(i)-coupled Src kinase signaling pathway. J. Cell Biol. 2000, 150:1057-1070.
249. Mitchell P., Bandello F., Schmidt-Erfurth U., Lang G.E., Massin P., Schlingemann R.O., Sutter F., Simader C., Burian G., Gerstner O., Weichselberger A. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmololgy 2011, 118:615-625.
250. Miyake K., Ibaraki N. Prostaglandins and cystoid macular edema. Surv. Ophthalmol. 2002, 47(Suppl 1):S203-S218.
251. Mizutani M., Kern T.S., Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J. Clin. Invest. 1996, 97:2883-2890.
252. Morita K., Tsukita S., Miyachi Y. Tight junction-associated proteins (occludin, ZO-1, claudin-1, claudin-4) in squamous cell carcinoma and Bowen's disease. Br. J. Dermatol. 2004, 151:328-334.
253. Motulsky E., Koch P., Janssens S., Lienart M., Vanbellinghen A.M., Bolaky N., Chan C.C., Caspers L., Martin-Martinez M.D., Xu H., Delporte C., Willermain F. Aquaporin expression in blood-retinal barrier cells during experimental autoimmune uveitis. Mol. Vis. 2010, 16:602-610.
254. Muller W.A. Mechanisms of leukocyte transendothelial migration. Annu. Rev. Pathol. 2011, 6:323-344.
255. Murakami T., Felinski E.A., Antonetti D.A. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J. Biol. Chem. 2009, 284:21036-21046.
256. Murakami T., Frey T., Lin C., Antonetti D.A. Protein kinase cbeta phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo. Diabetes 2012, 61:1573-1583.
257. Murphy-Ullrich J.E., Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000, 11:59-69.
258. Murugeswari P., Shukla D., Rajendran A., Kim R., Namperumalsamy P., Muthukkaruppan V. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease. Retina 2008, 28:817-824.
259. Musashi K., Kiryu J., Miyamoto K., Miyahara S., Katsuta H., Tamura H., Hirose F., Yoshimura N. Thrombin inhibitor reduces leukocyte-endothelial cell interactions and vascular leakage after scatter laser photocoagulation. Invest. Ophthalmol. Vis. Sci. 2005, 46:2561-2566.
260. Myles M.E., Neumann D.M., Hill J.M. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv. Drug Deliv. Rev. 2005, 57:2063-2079.
261. Nagasawa K., Chiba H., Fujita H., Kojima T., Saito T., Endo T., Sawada N. Possible involvement of gap junctions in the barrier function of tight junctions of brain and lung endothelial cells. J. Cell. Physiol. 2006, 208:123-132.
262. Nagase K., Tomi M., Tachikawa M., Hosoya K. Functional and molecular characterization of adenosine transport at the rat inner blood-retinal barrier. Biochim. Biophys. Acta 2006, 1758:13-19.
263. Nagelhus E.A., Horio Y., Inanobe A., Fujita A., Haug F.M., Nielsen S., Kurachi Y., Ottersen O.P. Immunogold evidence suggests that coupling of K+ siphoning and water transport in rat retinal Muller cells is mediated by a coenrichment of Kir4.1 and AQP4 in specific membrane domains. Glia 1999, 26:47-54.
264. Nagelhus E.A., Mathiisen T.M., Ottersen O.P. Aquaporin-4 in the central nervous system: cellular and subcellular distribution and coexpression with KIR4.1. Neuroscience 2004, 129:905-913.
265. Nakagawa S., Deli M.A., Nakao S., Honda M., Hayashi K., Nakaoke R., Kataoka Y., Niwa M. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell. Mol. Neurobiol. 2007, 27:687-694.
266. Nakagawa S., Deli M.A., Kawaguchi H., Shimizudani T., Shimono T., Kittel A., Tanaka K., Niwa M. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem. Int. 2009, 54:253-263.
267. Navaratna D., McGuire P.G., Menicucci G., Das A. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 2007, 56:2380-2387.
268. Negrete H.O., Lavelle J.P., Berg J., Lewis S.A., Zeidel M.L. Permeability properties of the intact mammalian bladder epithelium. Am. J. Physiol. 1996, 271:F886-F894.
269. Nielsen S., Smith B.L., Christensen E.I., Agre P. Distribution of the aquaporin CHIP in secretory and resorptive epithelia and capillary endothelia. Proc. Natl. Acad. Sci. U.S.A 1993, 90:7275-7279.
270. Niemela H., Elima K., Henttinen T., Irjala H., Salmi M., Jalkanen S. Molecular identification of PAL-E, a widely used endothelial-cell marker. Blood 2005, 106:3405-3409.
271. Nieuwdorp M., van Haeften T.W., Gouverneur M.C., Mooij H.L., van Lieshout M.H., Levi M., Meijers J.C., Holleman F., Hoekstra J.B., Vink H., Kastelein J.J., Stroes E.S. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006, 55:480-486.
272. Nishikawa T., Giardino I., Edelstein D., Brownlee M. Changes in diabetic retinal matrix protein mRNA levels in a common transgenic mouse strain. Curr. Eye Res. 2000, 21:581-587.
273. Nitta T., Hata M., Gotoh S., Seo Y., Sasaki H., Hashimoto N., Furuse M., Tsukita S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 2003, 161:653-660.
274. Nusrat A., Parkos C.A., Verkade P., Foley C.S., Liang T.W., Innis-Whitehouse W., Eastburn K.K., Madara J.L. Tight junctions are membrane microdomains. J. Cell Sci. 2000, 113:1771-1781.
275. Nyqvist D., Giampietro C., Dejana E. Deciphering the functional role of endothelial junctions by using in vivo models. EMBO Rep. 2008, 9:742-747.
276. Ogunshola O.O., Al-Ahmad A. HIF-1 at the blood-brain barrier: a mediator of permeability?. High Alt. Med. Biol. 2012, 13:153-161.
277. Oh H., Takagi H., Suzuma K., Otani A., Matsumura M., Honda Y. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J. Biol. Chem. 1999, 274:15732-15739.
278. Oh P., McIntosh D.P., Schnitzer J.E. Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. J. Cell Biol. 1998, 141:101-114.
279. Oh P., Borgstrom P., Witkiewicz H., Li Y., Borgstrom B.J., Chrastina A., Iwata K., Zinn K.R., Baldwin R., Testa J.E., Schnitzer J.E. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat. Biotechnol. 2007, 25:327-337.
280. Oh I.K., Kim S.W., Oh J., Lee T.S., Huh K. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr. Eye Res. 2010, 35:1116-1127.
281. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
282. Orsenigo F., Giampietro C., Ferrari A., Corada M., Galaup A., Sigismund S., Ristagno G., Maddaluno L., Young K.G., Franco D., Kurtcuoglu V., Poulikakos D., Baluk P., McDonald D., Grazia L.M., Dejana E. Phosphorylation of VE-cadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo. Nat. Commun. 2012, 3:1208.
283. Oshitari T., Polewski P., Chadda M., Li A.F., Sato T., Roy S. Effect of combined antisense oligonucleotides against high-glucose- and diabetes-induced overexpression of extracellular matrix components and increased vascular permeability. Diabetes 2006, 55:86-92.
284. Otero K., Martinez F., Beltran A., Gonzalez D., Herrera B., Quintero G., Delgado R., Rojas A. Albumin-derived advanced glycation end-products trigger the disruption of the vascular endothelial cadherin complex in cultured human and murine endothelial cells. Biochem. J. 2001, 359:567-574.
285. Paccola L., Costa R.A., Folgosa M.S., Barbosa J.C., Scott I.U., Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br. J. Ophthalmol. 2008, 92:76-80.
286. Palade G.E. Fine structure of blood capillaries. J. Appl. Physiol. 1953, 24:1424.
287. Palade G.E., Bruns R.R. Structural modulations of plasmalemmal vesicles. J. Cell Biol. 1968, 37:633-649.
288. Pannicke T., Iandiev I., Wurm A., Uckermann O., Vom H.F., Reichenbach A., Wiedemann P., Hammes H.P., Bringmann A. Diabetes alters osmotic swelling characteristics and membrane conductance of glial cells in rat retina. Diabetes 2006, 55:633-639.
289. Paolinelli R., Corada M., Orsenigo F., Dejana E. The molecular basis of the blood brain barrier differentiation and maintenance. Is it still a mystery?. Pharmacol. Res. 2011, 63:165-171.
290. Pappenheimer J.R., Renkin E.M., Borrero L.M. Filtration, diffusion and molecular sieving through peripheral capillary membranes; a contribution to the pore theory of capillary permeability. Am. J. Physiol. 1951, 167:13-46.
291. Paris L., Tonutti L., Vannini C., Bazzoni G. Structural organization of the tight junctions. Biochim. Biophys. Acta 2008, 1778:646-659.
292. Park D.S., Woodman S.E., Schubert W., Cohen A.W., Frank P.G., Chandra M., Shirani J., Razani B., Tang B., Jelicks L.A., Factor S.M., Weiss L.M., Tanowitz H.B., Lisanti M.P. Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. Am. J. Pathol. 2002, 160:2207-2217.
293. Parton R.G., Richards A.A. Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms. Traffic 2003, 4:724-738.
294. Pascariu M., Bendayan M., Ghitescu L. Correlated endothelial caveolin overexpression and increased transcytosis in experimental diabetes. J. Histochem. Cytochem. 2004, 52:65-76.
295. Patel J.I., Hykin P.G., Gregor Z.J., Boulton M., Cree I.A. Angiopoietin concentrations in diabetic retinopathy. Br. J. Ophthalmol. 2005, 89:480-483.
296. Peters A., Palay S., Webster H. The Fine Structure of the Nervous System: Neurons and Their Supporting Cells 1991, Oxford University Press, New York.
297. Pfister F., Feng Y., Vom H.F., Hoffmann S., Molema G., Hillebrands J.L., Shani M., Deutsch U., Hammes H.P. Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes 2008, 57:2495-2502.
298. Pfister F., Wang Y., Schreiter K., Vom H.F., Altvater K., Hoffmann S., Deutsch U., Hammes H.P., Feng Y. Retinal overexpression of angiopoietin-2 mimics diabetic retinopathy and enhances vascular damages in hyperglycemia. Acta Diabetol. 2010, 47:59-64.
299. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch. Ophthalmol. 2007, 125:318-324. PKC-DMES Study Group.
300. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005, 54:2188-2197. PKC-DRS Study Group.
301. Polt R., Porreca F., Szabo L.Z., Bilsky E.J., Davis P., Abbruscato T.J., Davis T.P., Harvath R., Yamamura H.I., Hruby V.J. Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A 1994, 91:7114-7118.
302. Predescu D., Vogel S.M., Malik A.B. Functional and morphological studies of protein transcytosis in continuous endothelia. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 287:L895-L901.
303. Predescu S.A., Predescu D.N., Timblin B.K., Stan R.V., Malik A.B. Intersectin regulates fission and internalization of caveolae in endothelial cells. Mol. Biol Cell. 2003, 14:4997-5010.
304. Predescu S.A., Predescu D.N., Malik A.B. Molecular determinants of endothelial transcytosis and their role in endothelial permeability. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 293:L823-L842.
305. Pruneau D., Belichard P., Sahel J.A., Combal J.P. Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy. Curr. Opin. Invest. Drugs 2010, 11:507-514.
306. Quigley M.G. Prognosis and retinal vessel features. Ophthalmology 2007, 114:1796-1797.
307. Rahman S., Rahman T., Ismail A.A., Rashid A.R. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes. Metab. 2007, 9:767-780.
308. Rakoczy E.P., Ali Rahman I.S., Binz N., Li C.R., Vagaja N.N., de Pinho M., Lai C.M. Characterization of a mouse model of hyperglycemia and retinal neovascularization. Am. J. Pathol. 2010, 177:2659-2670.
309. Raleigh D.R., Boe D.M., Yu D., Weber C.R., Marchiando A.M., Bradford E.M., Wang Y., Wu L., Schneeberger E.E., Shen L., Turner J.R. Occludin S408 phosphorylation regulates tight junction protein interactions and barrier function. J. Cell Biol. 2011, 193:565-582.
310. Rangasamy S., Srinivasan R., Maestas J., McGuire P.G., Das A. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2011, 52:3784-3791.
311. Raviola G. The structural basis of the blood-ocular barriers. Exp. Eye Res. 1977, 25:27-63.
312. Razani B., Engelman J.A., Wang X.B., Schubert W., Zhang X.L., Marks C.B., Macaluso F., Russell R.G., Li M., Pestell R.G., Di Vizio D., Hou H., Kneitz B., Lagaud G., Christ G.J., Edelmann W., Lisanti M.P. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 2001, 276:38121-38138.
313. Red-Horse K., Ferrara N. Vascular targeting via caveolae. Nat. Biotechnol. 2007, 25:431-432.
314. Rehak M., Hollborn M., Iandiev I., Pannicke T., Karl A., Wurm A., Kohen L., Reichenbach A., Wiedemann P., Bringmann A. Retinal gene expression and Muller cell responses after branch retinal vein occlusion in the rat. Invest. Ophthalmol. Vis. Sci. 2009, 50:2359-2367.
315. Reichenbach A., Wurm A., Pannicke T., Iandiev I., Wiedemann P., Bringmann A. Muller cells as players in retinal degeneration and edema. Graefes Arch. Clin. Exp. Ophthalmol. 2007, 245:627-636.
316. Rizzolo L.J., Peng S., Luo Y., Xiao W. Integration of tight junctions and claudins with the barrier functions of the retinal pigment epithelium. Prog. Retin. Eye Res. 2011, 30:296-323.
317. Rogers S., McIntosh R.L., Cheung N., Lim L., Wang J.J., Mitchell P., Kowalski J.W., Nguyen H., Wong T.Y. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010, 117:313-319.
318. Rosengren B.I., Rippe A., Rippe C., Venturoli D., Sward K., Rippe B. Transvascular protein transport in mice lacking endothelial caveolae. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1371-H1377.
319. Rothberg K.G., Ying Y.S., Kamen B.A., Anderson R.G. Cholesterol controls the clustering of the glycophospholipid-anchored membrane receptor for 5-methyltetrahydrofolate. J. Cell. Biol. 1990, 111:2931-2938.
320. Rothberg K.G., Heuser J.E., Donzell W.C., Ying Y.S., Glenney J.R., Anderson R.G. Caveolin, a protein component of caveolae membrane coats. Cell 1992, 68:673-682.
321. Roy S., Sato T., Paryani G., Kao R. Downregulation of fibronectin overexpression reduces basement membrane thickening and vascular lesions in retinas of galactose-fed rats. Diabetes 2003, 52:1229-1234.
322. Rudini N., Felici A., Giampietro C., Lampugnani M., Corada M., Swirsding K., Garre M., Liebner S., Letarte M., ten D.P., Dejana E. VE-cadherin is a critical endothelial regulator of TGF-beta signalling. EMBO J. 2008, 27:993-1004.
323. Ruiter D.J., Schlingemann R.O., Westphal J.R., Denijn M., Rietveld F.J., de Waal R.M. Angiogenesis in wound healing and tumor metastasis. Behring Inst. Mitt. 1993, 92:258-272.
324. Runkle E.A., Antonetti D.A. The blood-retinal barrier: structure and functional significance. Methods Mol. Biol. 2011, 686:133-148.
325. Saadoun S., Papadopoulos M.C., Davies D.C., Bell B.A., Krishna S. Increased aquaporin 1 water channel expression in human brain tumours. Br. J. Cancer 2002, 87:621-623.
326. Sagaties M.J., Raviola G., Schaeffer S., Miller C. The structural basis of the inner blood-retina barrier in the eye of Macaca mulatta. Invest. Ophthalmol. Vis. Sci. 1987, 28:2000-2014.
327. Saitou M., Ando-Akatsuka Y., Itoh M., Furuse M., Inazawa J., Fujimoto K., Tsukita S. Mammalian occludin in epithelial cells: its expression and subcellular distribution. Eur. J. Cell Biol. 1997, 73:222-231.
328. Saitou M., Fujimoto K., Doi Y., Itoh M., Fujimoto T., Furuse M., Takano H., Noda T., Tsukita S. Occludin-deficient embryonic stem cells can differentiate into polarized epithelial cells bearing tight junctions. J. Cell Biol. 1998, 141:397-408.
329. Samad A., Sultana Y., Aqil M. Liposomal drug delivery systems: an update review. Curr. Drug Deliv. 2007, 4:297-305.
330. Sander B., Larsen M., Moldow B., Lund-Andersen H. Diabetic macular edema: passive and active transport of fluorescein through the blood-retina barrier. Invest. Ophthalmol. Vis. Sci. 2001, 42:433-438.
331. Santibanez J.F., Blanco F.J., Garrido-Martin E.M., Sanz-Rodriguez F., del Pozo M.A., Bernabeu C. Caveolin-1 interacts and cooperates with the transforming growth factor-beta type I receptor ALK1 in endothelial caveolae. Cardiovasc. Res. 2008, 77:791-799.
332. Sato T.N., Tozawa Y., Deutsch U., Wolburg-Buchholz K., Fujiwara Y., Gendron-Maguire M., Gridley T., Wolburg H., Risau W., Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995, 376:70-74.
333. Scheppke L., Aguilar E., Gariano R.F., Jacobson R., Hood J., Doukas J., Cao J., Noronha G., Yee S., Weis S., Martin M.B., Soll R., Cheresh D.A., Friedlander M. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J. Clin. Invest. 2008, 118:2337-2346.
334. Schlingemann R.O., Dingjan G.M., Emeis J.J., Blok J., Warnaar S.O., Ruiter D.J. Monoclonal antibody PAL-E specific for endothelium. Lab. Invest. 1985, 52:71-76.
335. Schlingemann R.O., Bots G.T.A.M., Van Duinen S.G., Ruiter D.J. Differential expression of endotheliumspecific antigen PAL-E in vasculature of brain tumors and preexistent brain capillaries. Ann. N.Y. Acad. Sci. 1988, 465:111-114.
336. Schlingemann R.O., Hofman P., Anderson L., Troost D., van der G.R. Vascular expression of endothelial antigen PAL-E indicates absence of blood-ocular barriers in the normal eye. Ophthalmic Res. 1997, 29:130-138.
337. Schlingemann R.O., Rietveld F.J., Kwaspen F., van de Kerkhof P.C., de Waal R.M., Ruiter D.J. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am. J. Pathol. 1991, 138:1335-1347.
338. Schlingemann R.O., van Hinsbergh V.W. Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Br. J. Ophthalmol. 1997, 81:501-512.
339. Schlingemann R.O., Hofman P., Vrensen G.F., Blaauwgeers H.G. Increased expression of endothelial antigen PAL-E in human diabetic retinopathy correlates with microvascular leakage. Diabetologia 1999, 42:596-602.
340. Schlingemann R.O. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 2004, 242:91-101.
341. Schnitzer J. Astrocytes in mammalian retina. Prog. Ret. Eye Res. 1988, 7:209-212.
342. Schnitzer J.E. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am. J. Physiol. 1992, 262:H246-H254.
343. Schnitzer J.E., Liu J., Oh P. Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, and GTPases. J. Biol. Chem. 1995, 270:14399-14404.
344. Schubert W., Frank P.G., Woodman S.E., Hyogo H., Cohen D.E., Chow C.W., Lisanti M.P. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-name, restores normal microvascular permeability in Cav-1 null mice. J. Biol. Chem. 2002, 277:40091-40098.
345. Schubert W., Sotgia F., Cohen A.W., Capozza F., Bonuccelli G., Bruno C., Minetti C., Bonilla E., Dimauro S., Lisanti M.P. Caveolin-1(-/-)- and caveolin-2(-/-)-deficient mice both display numerous skeletal muscle abnormalities, with tubular aggregate formation. Am. J. Pathol. 2007, 170:316-333.
346. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
347. Sfikakis P.P., Markomichelakis N., Theodossiadis G.P., Grigoropoulos V., Katsilambros N., Theodossiadis P.G. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care 2005, 28:445-447.
348. Shajahan A.N., Timblin B.K., Sandoval R., Tiruppathi C., Malik A.B., Minshall R.D. Role of Src-induced dynamin-2 phosphorylation in caveolae-mediated endocytosis in endothelial cells. J. Biol. Chem. 2004, 279:20392-20400.
349. Shen L., Weber C.R., Turner J.R. The tight junction protein complex undergoes rapid and continuous molecular remodeling at steady state. J. Cell Biol. 2008, 181:683-695.
350. Shen W., Li S., Chung S.H., Gillies M.C. Retinal vascular changes after glial disruption in rats. J. Neurosci. Res. 2010, 88:1485-1499.
351. Shimura M., Nakazawa T., Yasuda K., Shiono T., Iida T., Sakamoto T., Nishida K. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am. J. Ophthalmol. 2008, 145:854-861.
352. Shue E.H., Carson-Walter E.B., Liu Y., Winans B.N., Ali Z.S., Chen J., Walter K.A. Plasmalemmal vesicle associated protein-1 (PV-1) is a marker of blood-brain barrier disruption in rodent models. BMC Neurosci. 2008, 9:29.
353. Siemerink M.J., Augustin A.J., Schlingemann R.O. Mechanisms of ocular angiogenesis and its molecular mediators. Dev. Ophthalmol. 2010, 46:4-20.
354. Silva P.S., Sun J.K., Aiello L.P. Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy. Semin. Ophthalmol. 2009, 24:93-99.
355. Simionescu N. The microvascular endothelium. Segmental differentiation transcytosis: selective distribution of anionic sites. Advances in Inflammation Research 1979, 61-70. Raven, New York. G. Weissman, B. Samuelson, R. Paoletti (Eds.).
356. Simionescu M. Receptor-mediated transcytosis of plasma molecules by vascular endothelium. Endothelial Cell Biology in Health and Disease 1988, 69-104. Plenum, New York. N. Simionescu, M. Simionescu (Eds.).
357. Simionescu M., Popov D., Sima A. Endothelial transcytosis in health and disease. Cell Tissue Res. 2009, 335:27-40.
358. Simionescu N., Siminoescu M., Palade G.E. Permeability of muscle capillaries to small heme-peptides. Evidence for the existence of patent transendothelial channels. J. Cell Biol. 1975, 64:586-607.
359. Simionescu N. Cellular aspects of transcapillary exchange. Physiol. Rev. 1983, 63:1536-1579.
360. Sivaprasad S., Bunce C., Crosby-Nwaobi R. Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database Syst. Rev. 2012, 2:CD004239.
361. Simó R., Villarroel M., Corraliza L., Hernández C., Garcia-Ramírez M. The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier-implications for the pathogenesis of diabetic retinopathy. J. Biomed. Biotechnol. 2010, 2010:190724.
362. Song L., Ge S., Pachter J.S. Caveolin-1 regulates expression of junction-associated proteins in brain microvascular endothelial cells. Blood 2007, 109:1515-1523.
363. Spindler V., Schlegel N., Waschke J. Role of GTPases in control of microvascular permeability. Cardiovasc. Res. 2010, 87:243-253.
364. Stamatovic S.M., Dimitrijevic O.B., Keep R.F., Andjelkovic A.V. Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J. Biol. Chem. 2006, 281:8379-8388.
365. Stan R.V., Ghitescu L., Jacobson B.S., Palade G.E. Isolation, cloning, and localization of rat PV-1, a novel endothelial caveolar protein. J. Cell Biol. 1999, 145:1189-1198.
366. Stefanec T. How the endothelium and its bone marrow-derived progenitors influence development of disease. Med. Hypotheses 2004, 62:247-251.
367. Stevenson B.R., Siliciano J.D., Mooseker M.S., Goodenough D.A. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J. Cell Biol. 1986, 103:755-766.
368. Stewart P.A., Tuor U.I. Blood-eye barriers in the rat: correlation of ultrastructure with function. J. Comp. Neurol. 1994, 340:566-576.
369. Stewart P.A. Endothelial vesicles in the blood-brain barrier: are they related to permeability?. Cell. Mol. Neurobiol. 2000, 20:149-163.
370. Stitt A.W., Bhaduri T., McMullen C.B., Gardiner T.A., Archer D.B. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol. Cell. Biol. Res. Commun. 2000, 3:380-388.
371. Stitt A., Gardiner T.A., Alderson N.L., Canning P., Frizzell N., Duffy N., Boyle C., Januszewski A.S., Chachich M., Baynes J.W., Thorpe S.R. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002, 51:2826-2832.
372. Strickland L.A., Jubb A.M., Hongo J.A., Zhong F., Burwick J., Fu L., Frantz G.D., Koeppen H. Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF). J. Pathol. 2005, 206:466-475.
373. Suhler E.B., Smith J.R., Wertheim M.S., Lauer A.K., Kurz D.E., Pickard T.D., Rosenbaum J.T. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch. Ophthalmol. 2005, 123:903-912.
374. Suhler E.B., Smith J.R., Giles T.R., Lauer A.K., Wertheim M.S., Kurz D.E., Kurz P.A., Lim L., Mackensen F., Pickard T.D., Rosenbaum J.T. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch. Ophthalmol. 2009, 127:819-822.
375. Sundstrom J.M., Tash B.R., Murakami T., Flanagan J.M., Bewley M.C., Stanley B.A., Gonsar K.B., Antonetti D.A. Identification and analysis of occludin phosphosites: a combined mass spectrometry and bioinformatics approach. J. Proteome Res. 2009, 8:808-817.
376. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., Sato T.N., Yancopoulos G.D. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87:1171-1180.
377. Tadayoni R., Paques M., Gaudric A., Vicaut E. Erythrocyte and leukocyte dynamics in the retinal capillaries of diabetic mice. Exp. Eye Res. 2003, 77:497-504.
378. Taddei A., Giampietro C., Conti A., Orsenigo F., Breviario F., Pirazzoli V., Potente M., Daly C., Dimmeler S., Dejana E. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat. Cell Biol. 2008, 10:923-934.
379. Takagi H., Koyama S., Seike H., Oh H., Otani A., Matsumura M., Honda Y. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 2003, 44:393-402.
380. Takata K., Kasahara T., Kasahara M., Ezaki O., Hirano H. Ultracytochemical localization of the erythrocyte/HepG2-type glucose transporter (GLUT1) in cells of the blood-retinal barrier in the rat. Invest. Ophthalmol. Vis. Sci. 1992, 33:377-383.
381. Tao-Cheng J.H., Nagy Z., Brightman M.W. Tight junctions of brain endothelium in vitro are enhanced by astroglia. J. Neurosci. 1987, 7:3293-3299.
382. Titchenell P.M., Lin C.M., Keil J.M., Sundstrom J.M., Smith C.D., Antonetti D.A. Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction. Biochem. J. 2012, 446:455-467.
383. Toda R., Kawazu K., Oyabu M., Miyazaki T., Kiuchi Y. Comparison of drug permeabilities across the blood-retinal barrier, blood-aqueous humor barrier, and blood-brain barrier. J. Pharm. Sci. 2011, 100:3904-3911.
384. Tout S., Chan-Ling T., Hollander H., Stone J. The role of Muller cells in the formation of the blood-retinal barrier. Neuroscience 1993, 55:291-301.
385. Tretiach M., Madigan M.C., Wen L., Gillies M.C. Effect of Muller cell co-culture on in vitro permeability of bovine retinal vascular endothelium in normoxic and hypoxic conditions. Neurosci. Lett. 2005, 378:160-165.
386. Tsukita S., Furuse M. Occludin and claudins in tight-junction strands: leading or supporting players?. Trends Cell Biol. 1999, 9:268-273.
387. Tsukita S., Furuse M., Itoh M. Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell Biol. 2001, 2:285-293.
388. Tsukita S., Yamazaki Y., Katsuno T., Tamura A., Tsukita S. Tight junction-based epithelial microenvironment and cell proliferation. Oncogene 2008, 27:6930-6938.
389. Tuma P.L., Hubbard A.L. Transcytosis: crossing cellular barriers. Physiol. Rev. 2003, 83:871-932.
390. Vacca A., Frigeri A., Ribatti D., Nicchia G.P., Nico B., Ria R., Svelto M., Dammacco F. Microvessel overexpression of aquaporin 1 parallels bone marrow angiogenesis in patients with active multiple myeloma. Br. J. Haematol. 2001, 113:415-421.
391. Van Geest R.J., Klaassen I., Vogels I.M., Van Noorden C.J., Schlingemann R.O. Differential TGF-{beta} signaling in retinal vascular cells: a role in diabetic retinopathy?. Invest. Ophthalmol. Vis. Sci. 2010, 51:1857-1865.
392. Van Geest R.J., Lesnik-Oberstein S.Y., Tan H.S., Mura M., Goldschmeding R., Van Noorden C.J., Klaassen I., Schlingemann R.O. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br. J. Ophthalmol. 2012, 96:587-590.
393. Van Itallie C.M., Anderson J.M. Claudins and epithelial paracellular transport. Annu. Rev. Physiol. 2006, 68:403-429.
394. Verkman A.S. Roles of aquaporins in kidney revealed by transgenic mice. Semin. Nephrol. 2006, 26:200-208.
395. Verkman A.S., Ruiz-Ederra J., Levin M.H. Functions of aquaporins in the eye. Prog. Retin. Eye Res. 2008, 27:420-433.
396. Vestweber D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler. Thromb. Vasc. Biol. 2008, 28:223-232.
397. Vestweber D., Winderlich M., Cagna G., Nottebaum A.F. Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol. 2009, 19:8-15.
398. Vink H., Duling B.R. Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ. Res. 1996, 79:581-589.
399. Vink H., Duling B.R. Capillary endothelial surface layer selectively reduces plasma solute distribution volume. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H285-H289.
400. Vinores S.A., McGehee R., Lee A., Gadegbeku C., Campochiaro P.A. Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats. J. Histochem. Cytochem. 1990, 38:1341-1352.
401. Vinores S.A., Xiao W.H., Shen J., Campochiaro P.A. TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J. Neuroimmunol. 2007, 182:73-79.
402. Vinten J., Johnsen A.H., Roepstorff P., Harpoth J., Tranum-Jensen J. Identification of a major protein on the cytosolic face of caveolae. Biochim. Biophys. Acta 2005, 1717:34-40.
403. Virgintino D., Robertson D., Errede M., Benagiano V., Tauer U., Roncali L., Bertossi M. Expression of caveolin-1 in human brain microvessels. Neuroscience 2002, 115:145-152.
404. Von Zglinicki T. Role of oxidative stress in telomere length regulation and replicative senescence. Ann. N.Y. Acad. Sci. 2000, 908:99-110.
405. Vyas S.P., Sihorkar V. Advances in Liposomal Therapeutics 2001, 230. CBS Publishers, New Delhi. S.P. Vyas, V. Dixit (Eds.).
406. Wagner R.C., Robinson C.S., Cross P.J., Devenny J.J. Endocytosis and exocytosis of transferrin by isolated capillary endothelium. Microvasc. Res. 1983, 25:387-396.
407. Wagner R.C., Chen S.C. Transcapillary transport of solute by the endothelial vesicular system: evidence from thin serial section analysis. Microvasc. Res. 1991, 42:139-150.
408. Wakabayashi Y., Usui Y., Okunuki Y., Kezuka T., Takeuchi M., Iwasaki T., Ohno A., Goto H. Increases of vitreous monocyte chemotactic protein 1 and interleukin 8 levels in patients with concurrent hypertension and diabetic retinopathy. Retina 2011, 31:1951-1957.
409. Wallez Y., Huber P. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim. Biophys. Acta 2008, 1778:794-809.
410. Walshe T.E., Saint-Geniez M., Maharaj A.S., Sekiyama E., Maldonado A.E., D'Amore P.A. TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS One 2009, 4:e5149.
411. Wang A., Hascall V.C. Hyaluronan structures synthesized by rat mesangial cells in response to hyperglycemia induce monocyte adhesion. J. Biol. Chem. 2004, 279:10279-10285.
412. Wenick A.S., Bressler N.M. Diabetic macular edema: current and emerging therapies. Middle East. Afr. J. Ophthalmol. 2012, 19:4-12.
413. Wheelock M.J., Johnson K.R. Cadherins as modulators of cellular phenotype. Annu. Rev. Cell Dev. Biol. 2003, 19:207-235.
414. Wisniewska-Kruk J., Hoeben K.A., Vogels I.M., Gaillard P.J., Van Noorden C.J., Schlingemann R.O., Klaassen I. A novel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytes. Exp. Eye Res. 2012, 96:181-190.
415. Witkin A.J., Brown G.C. Update on nonsurgical therapy for diabetic macular edema. Curr. Opin. Ophthalmol. 2011, 22:185-189.
416. Witmer A.N., Blaauwgeers H.G., Weich H.A., Alitalo K., Vrensen G.F., Schlingemann R.O. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest. Ophthalmol. Vis. Sci. 2002, 43:849-857.
417. Witmer A.N., Vrensen G.F., Van Noorden C.J., Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 2003, 22:1-29.
418. Witmer A.N., van Blijswijk B.C., Van Noorden C.J., Vrensen G.F., Schlingemann R.O. In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A. J. Histochem. Cytochem. 2004, 52:39-52.
419. Wolburg H., Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul. Pharmacol. 2002, 38:323-337.
420. Wolburg H., Wolburg-Buchholz K., Kraus J., Rascher-Eggstein G., Liebner S., Hamm S., Duffner F., Grote E.H., Risau W., Engelhardt B. Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol. 2003, 105:586-592.
421. Wolburg H., Wolburg-Buchholz K., Engelhardt B. Diapedesis of mononuclear cells across cerebral venules during experimental autoimmune encephalomyelitis leaves tight junctions intact. Acta Neuropathol. 2005, 109:181-190.
422. Wolburg H. The endothelial frontier. Blood-Brain Interface: From Ontogeny to Artificial Barriers 2006, 77-109. Wiley-VCH, Weinheim, Germany. R. Dermietzel, D.C. Spray, M. Nedergaard (Eds.).
423. Wolburg H., Noell S., Mack A., Wolburg-Buchholz K., Fallier-Becker P. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res. 2009, 335:75-96.
424. Wright T.J., Leach L., Shaw P.E., Jones P. Dynamics of vascular endothelial-cadherin and beta-catenin localization by vascular endothelial growth factor-induced angiogenesis in human umbilical vein cells. Exp. Cell Res. 2002, 280:159-168.
425. Wu L., Hernandez-Bogantes E., Roca J.A., Arevalo J.F., Barraza K., Lasave A.F. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina 2011, 31:298-303.
426. Xia P., Aiello L.P., Ishii H., Jiang Z.Y., Park D.J., Robinson G.S., Takagi H., Newsome W.P., Jirousek M.R., King G.L. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 1996, 98:2018-2026.
427. Xu H., Chen M., Forrester J.V. Para-inflammation in the aging retina. Prog. Retin. Eye Res. 2009, 28:348-368.
428. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J. Biophys. Biochem. Cytol. 1955, 1:445-458.
429. Yan J., Zhou B., Taheri S., Shi H. Differential effects of HIF-1 inhibition by YC-1 on the overall outcome and blood-brain barrier damage in a rat model of ischemic stroke. PLoS One 2011, 6:e27798.
430. Yeh W.L., Lu D.Y., Lin C.J., Liou H.C., Fu W.M. Inhibition of hypoxia-induced increase of blood-brain barrier permeability by YC-1 through the antagonism of HIF-1alpha accumulation and VEGF expression. Mol. Pharmacol. 2007, 72:440-449.
431. Zhang J., Gerhardinger C., Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 2002, 51:3499-3504.
432. Zhang S.X., Wang J.J., Gao G., Shao C., Mott R., Ma J.X. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J. 2006, 20:323-325.
433. Ziello J.E., Jovin I.S., Huang Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J. Biol. Med. 2007, 80:51-60.
434. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.